I will discuss the potential impact of pre-existing immunity on the efficacy of AAV-based gene therapy and provide a brief overview of mitigation strategies. Additionally, I will present preliminary non-clinical data from a few approaches we have evaluated aiming to remove existing antibodies or prevent the development of treatment-induced antibodies.